Home › Compare › PVARF vs ABBV
PVARF yields 0.87% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, PVARF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PVARF + ABBV for your $10,000?
Porvair plc, a filtration and environmental technology company, designs, manufactures, and sells filtration and separation equipment primarily in the United Kingdom. It operates in three segments: Aerospace & Industrial, Laboratory, and Metal Melt Quality. The Aerospace & Industrial segment designs and manufactures a range of specialist filtration equipment for aerospace, energy, and industrial applications. The Laboratory segment is involved in the design and manufacture of instruments and consumables for use in environmental and bioscience laboratories with a focus on water analysis instruments, diagnostics, and sample preparation equipment. This segment also produces a range of laboratory microplates, filters, tubing, and associated consumables for use in diagnostics, sample preparation and chromatography applications; and water analysis equipment. The Metal Melt Quality segment designs and manufactures porous ceramic filters for the filtration of molten metals. It provides patent protected filters for the aluminum cast house industry; and the filtration of gray and ductile iron, as well as filtration of super alloy filters used in the manufacture of turbine blades. The company is also involved in trading activities. It also operates in Continental Europe, the United States, South America, Asia, and Africa, as well as other NAFTA countries. Porvair plc was incorporated in 1982 and is headquartered in King's Lynn, the United Kingdom.
Full PVARF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.